Modified FOLFOX-6 Plus Bevacizumab Chemotherapy for Metastatic Colorectal Cancer in Patients Receiving Hemodialysis: A Report of Three Cases and Review of the Literature
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Modified FOLFOX-6 Plus Bevacizumab Chemotherapy for Metastatic Colorectal Cancer in Patients Receiving Hemodialysis: A Report of Three Cases and Review of the Literature ; volume:12 ; number:2 ; year:2019 ; pages:657-665
Case reports in oncology ; 12, Heft 2 (2019), 657-665
- Creator
-
Funasaka, Chikako
Kanemasa, Yusuke
Shimoyama, Tatsu
Ohta, Akihito
Omuro, Yasushi
- DOI
-
10.1159/000502512
- URN
-
urn:nbn:de:101:1-2019091200141498907436
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Funasaka, Chikako
- Kanemasa, Yusuke
- Shimoyama, Tatsu
- Ohta, Akihito
- Omuro, Yasushi
Other Objects (12)
Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab
Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Healthcare costs in patients with metastatic lung cancer receiving chemotherapy
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report
Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality
Periodontal disease in a patient receiving Bevacizumab: a case report
Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel
Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab
Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Healthcare costs in patients with metastatic lung cancer receiving chemotherapy
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report
Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality
Periodontal disease in a patient receiving Bevacizumab: a case report
Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel
Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab
Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Healthcare costs in patients with metastatic lung cancer receiving chemotherapy
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report
Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality
Periodontal disease in a patient receiving Bevacizumab: a case report